P-652 RCT to evaluate the necessity of routine luteal phase support after ovarian stimulation by oral ovulogens in intrauterine insemination (IUI) cycles

Abstract Study question 1. Is it beneficial to provide luteal phase support in each IUI cycle stimulated by oral ovulogens ? Summary answer Luteal with progesterone makes no significant difference clinical pregnancy rate ovulogen cycles. What is known already ART (assisted reproductive techniques) involves superovulation achieve the development of multiple follicles. This produces supraphysiological E2 levels that causes feedback inhibition FSH and LH leading defect. In IUI,only few follicles develop ,so above phenomenon rarely seen. Today widespread use practice has become a habit, instead need, adding burden medication cost patient without much evidence recommend it. design, size, duration Prospective Randomized control over 1 year 200 cycles randomized either supplementing tab dydrogesterone (Group A ,no.100) or not B, No. 100) as per inclusion(Unexplained infertility,Mild male factor,Donor sperm IUI, PCOD,Coital factors,Mild endometriosis) exclusion criteria(IUI gonatotropin, age more than 38 years, thin endometrium ,previous two failures, history suggestive defect, recurrent loss, structural uterine anomaly, endocrine autoimmune diseases) Participants/materials, setting, methods Transvaginal scan was conducted on day 2 , followed ovarian stimulation letrozole 2.5 mg for 5 days. HCG trigger (10000IU) given When follicle reached 18- 24mm >7mm timed 36 hours after. Computer generated random allocation done one group receiving 10mg twice day(Group A)and other LPS(Group B).Outcome study studied terms USG. Main results role chance Among patients recruited, infertility observed be primary 74% cases Group B 72% whereas secondary 26% 28% (P = 0.75). included mild factor 29%, 24% polycystic syndrome, 17 % tubal, 15% poor reserve, 9% unexplained 6% had endometriosis. Whereas A, PCOS (25%),male (21%),poor reserve 20%, endometriosis 8% tubal infertility. patients, mean thickness Band were 8.46 ± 1.36mm 8.44 1.17mm respectively. Conception reported positive urine test . 23% test. Whereas, controls 21% test, being statistically non-significant (p value 0.733) Outcomes expressed described presence intrauterine sac foetal heart rate. Clinical 22% nonsignificant 0.755). Limitations, reasons caution Due limited period hence restricted sample trial needs extended larger size further interpretation. Further subgroup analysis when recruited. Wider implications findings suggested does significantly affect .Our could basis determine whether treatment form can reduced such patients. Trial registration number applicable